TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29513303

Group type: EXPERIMENTAL
Intervention: Chewing gum 3 times a day postoperatively
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (no chewing gum)
Number of subjects: 89
Study: 27802585

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS (2 mA/20 min for 10 sessions)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Anodal tDCS (2 mA/20 min for 10 sessions)
Number of subjects: 12
Study: 24184576

Group type: EXPERIMENTAL
Intervention: Intranasally administered oxytocin (16 IU)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 22044433

Group type: EXPERIMENTAL
Intervention: Flupirtine (400 mg/day, titrated to 600 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tolterodine (4 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20688811

Group type: EXPERIMENTAL
Intervention: Phonological training for 6 months
Number of subjects: 14
Study: 18199844

Group type: EXPERIMENTAL
Intervention: CAPD with a target creatinine clearance > or =60 L/wk/1.73 m(2)
Number of subjects: 965

Group type: COMPARATOR
Intervention: Standard 4 x 2L continuous ambulatory peritoneal dialysis (CAPD)
Number of subjects: 965

Group type: EXPERIMENTAL
Intervention: Volume removal
Number of subjects: 965
Study: 15698708

Group type: EXPERIMENTAL
Intervention: Safety harness
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Light touch
Number of subjects: 60

Group type: COMPARATOR
Intervention: No visual information
Number of subjects: 60
Study: 12960652

Group type: EXPERIMENTAL
Intervention: Epigastric impedance measurement in patients with gastrointestinal diseases
Number of subjects: 61

Group type: COMPARATOR
Intervention: Epigastric impedance measurement in healthy infants (control group)
Number of subjects: 61
Study: 10533859

Group type: EXPERIMENTAL
Intervention: Nurse practitioners
Number of subjects: 1453

Group type: COMPARATOR
Intervention: Junior doctors
Number of subjects: 1453
Study: 8627061

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐n3 (IFN‐alpha n3) 1 mega‐IU (MIU)/dose
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐n3 (IFN‐alpha n3) 5 MIU/dose
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐n3 (IFN‐alpha n3) maximum tolerated dose
Number of subjects: 20
Study: 1471382

Group type: EXPERIMENTAL
Intervention: 20 mg pantoprazole o.m.
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: 40 mg pantoprazole o.m.
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: 80 mg pantoprazole o.m.
Number of subjects: 219
Study: 6363731

Group type: EXPERIMENTAL
Intervention: Smoking intervention
Number of subjects: 935

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 935
Study: 31133558

Group type: EXPERIMENTAL
Intervention: Transcranial random noise stimulation (tRNS) over visual areas coupled with visual training for 10 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control conditions (not specified)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anodal stimulation (not specified)
Number of subjects: 0
Study: 29360237

Group type: EXPERIMENTAL
Intervention: 4-year lifestyle intervention (6 face-to-face sessions and 2 telephone calls in the first year, 2 individual sessions and 2 telephone calls in subsequent years)
Number of subjects: 1180

Group type: EXPERIMENTAL
Intervention: 4-year lifestyle intervention (specifically for overweight women)
Number of subjects: 1180

Group type: EXPERIMENTAL
Intervention: 4-year lifestyle intervention
Number of subjects: 1180

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1180

Group type: COMPARATOR
Intervention: Standard care (specifically for overweight women)
Number of subjects: 1180
Study: 27328975

Group type: EXPERIMENTAL
Intervention: CARE Plus intervention
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control group (treatment as usual)
Number of subjects: 152
Study: 24820928

Group type: EXPERIMENTAL
Intervention: 6-minute walking test (6MWT)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Cycle ergometry
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 74

Group type: COMPARATOR
Intervention: Normal subjects (control group)
Number of subjects: 74
Study: 21778151

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 29

Group type: COMPARATOR
Intervention: Bupropion XL
Number of subjects: 29
Study: 20108156

Group type: EXPERIMENTAL
Intervention: 10 ml of 0.5% bupivacaine (50 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 10 ml of sterile water
Number of subjects: 50
Study: 18614815

Group type: EXPERIMENTAL
Intervention: High PUFA diet
Number of subjects: 14

Group type: COMPARATOR
Intervention: High SFA diet
Number of subjects: 14
Study: 15641037

Group type: EXPERIMENTAL
Intervention: Cisplatin 70 mg/m2 on Day 1, etoposide 50 mg/m2 on Days 1-3, and gemcitabine 1000 mg/m2 on Days 1 and 8 (PEG)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Cisplatin 70 mg/m2 on Day 1 plus gemcitabine 1250 mg/m2 on Days 1 and 8 (PG)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: PEG regimen
Number of subjects: 140

Group type: COMPARATOR
Intervention: PG regimen
Number of subjects: 140
Study: 15553066

Group type: EXPERIMENTAL
Intervention: PEG-IFN-s (pegylated interferon alpha)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination with ribavirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monotherapy with PEG-IFN-s
Number of subjects: 0
Study: 10470391

Group type: EXPERIMENTAL
Intervention: Droperidol 10 micrograms/kg
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Droperidol 20 micrograms/kg
Number of subjects: 228

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Both doses of droperidol
Number of subjects: 228
Study: 8759084

Group type: EXPERIMENTAL
Intervention: 1 mg warfarin
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 300 mg aspirin
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Conventional warfarin therapy
Number of subjects: 51
Study: 8290745

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (500 micrograms day-1) via Diskhaler inhaler
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (500 micrograms day-1) via pressurized inhaler
Number of subjects: 585

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (1000 micrograms day-1) via pressurized inhaler
Number of subjects: 585
Study: 3548312

Group type: EXPERIMENTAL
Intervention: Starch-rich foods (beans, lentils, rice, spaghetti, potato, bread)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Mixed meals (isoglucido-lipido-protidic)
Number of subjects: 18
Study: 29743224

Group type: EXPERIMENTAL
Intervention: HIT tools and educational materials
Number of subjects: 23

Group type: COMPARATOR
Intervention: HIT tools, educational materials, and individualized implementation support with a practice coach
Number of subjects: 23
Study: 27575820

Group type: EXPERIMENTAL
Intervention: Y90 radioembolization
Number of subjects: 179

Group type: COMPARATOR
Intervention: cTACE
Number of subjects: 179
Study: 25854786

Group type: EXPERIMENTAL
Intervention: Triple therapy + Coenzyme Q10 (CoQ10)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Triple therapy
Number of subjects: 100
Study: 24134498

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 329
Study: 21816779

Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acids (MUFA)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Polyunsaturated fatty acids (PUFA)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: MUFA/PUFA ratio
Number of subjects: 152
Study: 19451658

Group type: EXPERIMENTAL
Intervention: Fear of Falling (FoF) group
Number of subjects: 100

Group type: COMPARATOR
Intervention: No Fear of Falling (no-FoF) group
Number of subjects: 100
Study: 16681406

Group type: EXPERIMENTAL
Intervention: Soft palate repair first, followed by hard palate and lip repair 3 months later
Number of subjects: 47

Group type: COMPARATOR
Intervention: Hard palate and lip repair first, followed by soft palate repair 3 months later
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Soft palate repair first
Number of subjects: 47

Group type: COMPARATOR
Intervention: Hard palate and lip repair first
Number of subjects: 47
Study: 14647988

Group type: EXPERIMENTAL
Intervention: FDG-PET/CT imaging
Number of subjects: 27

Group type: COMPARATOR
Intervention: CT alone
Number of subjects: 27

Group type: COMPARATOR
Intervention: FDG-PET alone
Number of subjects: 27

Group type: COMPARATOR
Intervention: CT and FDG-PET read side by side
Number of subjects: 27

Group type: COMPARATOR
Intervention: Regional lymph node involvement
Number of subjects: 27
Study: 11584209

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate solution (0.025 mg/kg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Tap water
Number of subjects: 15
Study: 10561250

Group type: EXPERIMENTAL
Intervention: Doxorubicin (50 mg/m(2) IV over 15 minutes) and docetaxel (75 mg/m(2) IV over 1 hour) every 14 days for four cycles
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Doxorubicin and docetaxel (3-week schedule)
Number of subjects: 42
Study: 8018023

Group type: EXPERIMENTAL
Intervention: AIDS preface statement
Number of subjects: 400

Group type: COMPARATOR
Intervention: General preface statement
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Both prefaces (AIDS and General)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Responders vs Nonresponders
Number of subjects: 400
Study: 2689679

Group type: EXPERIMENTAL
Intervention: Vincristine 2 mg or vindesine 3 mg per week, prednisolone 20 to 30 mg per day, and partly 6-mercaptopurine 50 to 100 mg, combined with allopurinol 200 to 300 mg per day for 2 to 3 weeks.
Number of subjects: 83

Group type: COMPARATOR
Intervention: Conventional treatment with busulfan or other alkylating agents.
Number of subjects: 83
Study: 5677210

Group type: EXPERIMENTAL
Intervention: Diet with tolbutamide, chlorpropamide, or metformin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total starvation in obese subjects
Number of subjects: 0
Study: 30719981

Group type: EXPERIMENTAL
Intervention: MiStent (sirolimus-eluting stent)
Number of subjects: 1398

Group type: COMPARATOR
Intervention: XIENCE (everolimus-eluting stent)
Number of subjects: 1398
Study: 29656663

Group type: EXPERIMENTAL
Intervention: Intranasal esketamine (84 mg)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 26581034

Group type: EXPERIMENTAL
Intervention: BTHC blood bags
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline injection (control phase)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DEHP-containing blood bags
Number of subjects: 0
Study: 25173516

Group type: EXPERIMENTAL
Intervention: Darapladib (160 mg once daily)
Number of subjects: 13026

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13026
Study: 22447213

Group type: EXPERIMENTAL
Intervention: Short consent form (3602 words, 5 pages)
Number of subjects: 581

Group type: COMPARATOR
Intervention: Standard consent form (10,459 words, 11 pages)
Number of subjects: 581
Study: 20429946

Group type: EXPERIMENTAL
Intervention: Population based screening by mail
Number of subjects: 187

Group type: COMPARATOR
Intervention: General practice recruitment
Number of subjects: 187
Study: 18209107

Group type: EXPERIMENTAL
Intervention: Outreach facilitation intervention
Number of subjects: 54
Study: 15792400

Group type: EXPERIMENTAL
Intervention: New 625 mg nelfinavir tablet (test formulation)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Commercial 250 mg nelfinavir tablet (reference formulation)
Number of subjects: 52
Study: 12851606

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy with or without abciximab
Number of subjects: 878

Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 878
Study: 10533870

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate with chlorofluorocarbons as propellant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluticasone propionate with hydrofluoroalkane as propellant
Number of subjects: 0
Study: 2196670

Group type: EXPERIMENTAL
Intervention: norfloxacin 200 mg twice daily for 7 days
Number of subjects: 343

Group type: COMPARATOR
Intervention: pivmecillinam 200 mg 3 times daily for 7 days
Number of subjects: 343
Study: 351715

Group type: EXPERIMENTAL
Intervention: Dopamine and prostaglandin A1 administered conjointly
Number of subjects: 6

Group type: COMPARATOR
Intervention: Prostaglandin A1
Number of subjects: 6

Group type: COMPARATOR
Intervention: Dopamine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Dopamine and prostaglandin A1
Number of subjects: 6
Study: 29959667

Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 28668289

Group type: EXPERIMENTAL
Intervention: Oral misoprostol 25 μg every 2 h (maximum of 12 doses)
Number of subjects: 602

Group type: COMPARATOR
Intervention: Transcervical Foley catheter (silicone, size 18 F with 30 mL balloon)
Number of subjects: 602
Study: 26484463

Group type: EXPERIMENTAL
Intervention: Nitrous Oxide (N2O)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Oxygen (O2)
Number of subjects: 78
Study: 23828223

Group type: EXPERIMENTAL
Intervention: HQK-1001 at 30 mg/kg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: HQK-1001 at 40 mg/kg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: HQK-1001 at 50 mg/kg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: HQK-1001 plus hydroxyurea
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: HQK-1001
Number of subjects: 52
Study: 22859239

Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg at weeks 0, 4, and 16
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 121
Study: 19453319

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Proton Pump Inhibitors
Number of subjects: 9
Study: 17608341

Group type: EXPERIMENTAL
Intervention: DIAM interspinous process spacer (Group D)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 62
Study: 15196108

Group type: EXPERIMENTAL
Intervention: Epidural sufentanil (50 microg) pre-emptively
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (sufentanil at the end of surgery)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 12596623

Group type: EXPERIMENTAL
Intervention: One-dose azithromycin prophylaxis
Number of subjects: 122

Group type: COMPARATOR
Intervention: No prophylaxis (Control)
Number of subjects: 122
Study: 9649909

Group type: EXPERIMENTAL
Intervention: Supine SBP in normotensive subjects
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Supine SBP in borderline hypertensive subjects
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: ERG DBP in mildly hypertensive subjects
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: ERG SBP in mildly hypertensive subjects
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: OSBP in normotensive subjects
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: ODB in normotensive and mildly hypertensive subjects
Number of subjects: 97
Study: 8127110

Group type: EXPERIMENTAL
Intervention: Diltiazem (0.1 mg/kg per hour)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Nitroglycerin (1 micrograms/kg per minute)
Number of subjects: 120
Study: 2567150

Group type: EXPERIMENTAL
Intervention: Sulphasalazine (2 g daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hydroxychloroquine (400 mg daily for months 0‐6, then 200 mg daily)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sulphasalazine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hydroxychloroquine
Number of subjects: 60
Study: 6254159

Group type: EXPERIMENTAL
Intervention: Veralipride
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 31365536

Group type: EXPERIMENTAL
Intervention: Lifetime prevalence of sexual violence (SV)
Number of subjects: 836

Group type: EXPERIMENTAL
Intervention: Sexual violence by age 15
Number of subjects: 836

Group type: EXPERIMENTAL
Intervention: Factors associated with SV by a partner
Number of subjects: 836

Group type: EXPERIMENTAL
Intervention: Factors associated with SV by a non-partner
Number of subjects: 836

Group type: EXPERIMENTAL
Intervention: SV experiences in childhood or adulthood
Number of subjects: 836
Study: 28722422

Group type: EXPERIMENTAL
Intervention: 3,4-Methylenedioxymethamphetamine (MDMA)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 26545986

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering (target systolic BP <125 mmHg)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Guideline blood pressure lowering (target systolic BP <140 mmHg)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Intensive lipid lowering (target LDL cholesterol <1.4 mmol/L)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Guideline lipid lowering (target LDL cholesterol <3 mmol/L)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Feasibility of performing a large trial of one or both interventions
Number of subjects: 83
Study: 24180162

Group type: EXPERIMENTAL
Intervention: 0.25% ropivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (normal saline solution)
Number of subjects: 60
Study: 22475305

Group type: EXPERIMENTAL
Intervention: G‐CSF 10 μg/kg/day for 3 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-G‐CSF group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (healthy newborns)
Number of subjects: 60
Study: 20513340

Group type: EXPERIMENTAL
Intervention: LA Health Internet intervention
Number of subjects: 773
Study: 17165082

Group type: EXPERIMENTAL
Intervention: Verapamil hydrochloride (isoptin 240 mg KKH tablets, oral t.i.d.)
Number of subjects: 95

Group type: COMPARATOR
Intervention: No specific therapy (control group)
Number of subjects: 95
Study: 16178942

Group type: EXPERIMENTAL
Intervention: Medical management plus acupuncture
Number of subjects: 74

Group type: COMPARATOR
Intervention: Medical management only
Number of subjects: 74
Study: 12174946

Group type: EXPERIMENTAL
Intervention: Sequential Doxorubicin (A) -> Docetaxel (T) -> CMF
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Sequential accelerated A -> T -> CMF
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Combination therapy: A 50 mg/m2 + T 75 mg/m2 q 3 wks x 4, followed by CMF x 4
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Sequential T -> A -> CMF
Number of subjects: 93
Study: 10545692

Group type: COMPARATOR
Intervention: Contralateral movement in controls
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ipsilateral movement (affected hand) in patients
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Contralateral movement (affected hand) in patients at T1 and T2
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Contralateral movement (affected hand) in patients at T3
Number of subjects: 30
Study: 8655009

Group type: EXPERIMENTAL
Intervention: Antinuclear antibodies (ANA) detected in women with endometriosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antinuclear antibodies (ANA) detected in women with idiopathic infertility
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antinuclear antibodies (ANA) detected in women with hypothalamic‐pituitary dysfunction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antinuclear antibodies (ANA) detected in healthy nonpregnant women
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Association of ANA with negative postcoital test and spontaneous abortions in endometriosis and idiopathic infertility
Number of subjects: 0
Study: 2216006

Group type: EXPERIMENTAL
Intervention: Optimal hydration (Group B)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (Group A)
Number of subjects: 26
Study: 7433479

Group type: EXPERIMENTAL
Intervention: Cinnarizine (75 mg 3-times daily)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cinnarizine (12-month follow-up)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (12-month follow-up)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cinnarizine
Number of subjects: 45
Study: 31753880

Group type: EXPERIMENTAL
Intervention: Mindful Eating (ME) + Treatment as Usual (TAU)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 76
Study: 28765644

Group type: EXPERIMENTAL
Intervention: Increased triglycerides (TG)
Number of subjects: 14864

Group type: EXPERIMENTAL
Intervention: TG/HDL
Number of subjects: 14864

Group type: EXPERIMENTAL
Intervention: Decreased high density lipoprotein (HDL)
Number of subjects: 14864

Group type: EXPERIMENTAL
Intervention: MTHFR 677 CT genotype
Number of subjects: 14864
Study: 25765294

Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% solution twice daily for 3 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Mometasone furoate 0.1% cream once daily for 3 months
Number of subjects: 30
Study: 23389755

Group type: EXPERIMENTAL
Intervention: gabapentin (GBP; up to 1,200 mg for 39 days) and flumazenil (FMZ) infusions (2 days)
Number of subjects: 48

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 48
Study: 21414978

Group type: EXPERIMENTAL
Intervention: Empathic attitude during preoperative visit
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Continuous care (same anaesthesiologist for preoperative visit and anaesthesia)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Neutral attitude during preoperative visit
Number of subjects: 136

Group type: COMPARATOR
Intervention: Divided care (preoperative visit and anaesthesia by different anaesthesiologists)
Number of subjects: 136
Study: 20008239

Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies and dose‐intensified approaches including autologous stem cell transplantation (ASCT) strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emerging strategies such as proteasome inhibitors, IMIDs, mTOR inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination strategies currently being investigated in numerous trials
Number of subjects: 0
Study: 18041162

Group type: EXPERIMENTAL
Intervention: FDC isosorbide dinitrate/hydralazine
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: ACE inhibitors and/or ARBs
Number of subjects: 1050

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1050